Cytek Biosciences, Inc. (NASDAQ:CTKB) Analysts Are Pretty Bullish On The Stock After Recent Results

Simply Wall St.11-07 20:53

Last week, you might have seen that Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly result to the market. The early response was not positive, with shares down 4.9% to US$5.83 in the past...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681817648?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557","is_english":true,"pubTime":"2026-11-07 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681817648","market":"us","top_or_hot":-1,"title":"Cytek Biosciences, Inc. (NASDAQ:CTKB) Analysts Are Pretty Bullish On The Stock After Recent Results","media":"Simply Wall St.","content":"<div>\n<p>Last week, you might have seen that Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly result to the market. The early response was not positive, with shares down 4.9% to US$5.83 in the past...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctkb/cytek-biosciences/news/cytek-biosciences-inc-nasdaqctkb-analysts-are-pretty-bullish\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytek Biosciences, Inc. (NASDAQ:CTKB) Analysts Are Pretty Bullish On The Stock After Recent Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytek Biosciences, Inc. (NASDAQ:CTKB) Analysts Are Pretty Bullish On The Stock After Recent Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-07 20:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctkb/cytek-biosciences/news/cytek-biosciences-inc-nasdaqctkb-analysts-are-pretty-bullish><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week, you might have seen that Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly result to the market. The early response was not positive, with shares down 4.9% to US$5.83 in the past...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctkb/cytek-biosciences/news/cytek-biosciences-inc-nasdaqctkb-analysts-are-pretty-bullish\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctkb/cytek-biosciences/news/cytek-biosciences-inc-nasdaqctkb-analysts-are-pretty-bullish","article_id":"2681817648","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctkb/cytek-biosciences/news/cytek-biosciences-inc-nasdaqctkb-analysts-are-pretty-bullish","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681817648","pubTimestamp":1794056014,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSimply Wall StNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Cytek Biosciences, Inc.（纳斯达克股票代码：CTKB）分析师在最近的业绩公布后相当看好该股","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/5f68fcb735a574b953f9b5db9cf3bdbe","symbols_score_info":{"QQQ":0.6,"NDX":0.6,"FTEC":0.6,"QQQE":0.6,"JEPQ":0.6,"QQQA":0.6,"GPIQ":0.6,"TQQQ":0.6,"ONEQ":0.6,"NQmain":0.6,"QID":0.6,"IYW":0.6,".IXIC":1.5,"MNQmain":0.6,"QLD":0.6,"TQQY":0.6,"03086":0.6,"QYLG":0.6,"QQQM":0.6,"CTKB":1.5,"SQQQ":0.6,"TECS":0.6,"QQQJ":0.6,"PSQ":0.6,"QQQY":0.6,"QDTE":0.6},"content_text":"Last week, you might have seen that Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly result to the market. The early response was not positive, with shares down 4.9% to US$5.83 in the past week.        It looks like the results were pretty good overall. While revenues of US$53m were in line with analyst predictions, statutory losses were much smaller than expected, with Cytek Biosciences losing US$0.05 per share.      This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business.  Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Cytek Biosciences after the latest results.  We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqGS:CTKB Earnings and Revenue Growth November 7th 2026 Following the latest results, Cytek Biosciences' three analysts are now forecasting revenues of US$222.8m in 2027. This would be an okay 7.3% improvement in revenue compared to the last 12 months.      Losses are predicted to fall substantially, shrinking 59% to US$0.25.       Before this latest report, the consensus had been expecting revenues of US$222.8m and US$0.27 per share in losses.         It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.      View our latest analysis for Cytek Biosciences   The average price target rose 11% to US$6.17, with the analysts signalling that the forecast reduction in losses would be a positive for the stock's valuation.        There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business.  There are some variant perceptions on Cytek Biosciences, with the most bullish analyst valuing it at US$7.50 and the most bearish at US$5.00 per share.   As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.      These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Cytek Biosciences' past performance and to peers in the same industry. We would highlight that Cytek Biosciences' revenue growth is expected to slow, with the forecast 5.8% annualised growth rate until the end of 2027 being well below the historical 9.0% p.a. growth over the last five years.    Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 6.9% annually.  So it's pretty clear that, while Cytek Biosciences' revenue growth is expected to slow, it's expected to grow roughly in line with the industry.     AdvertisementThe Bottom Line  The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year.        They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry.       We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.   Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings.   We have estimates - from multiple Cytek Biosciences analysts - going out to 2028, and you can see them free on our platform here.  You should always think about risks though. Case in point, we've spotted   1 warning sign for Cytek Biosciences  you should be aware of.   New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681817648","isCrawlerRequest":true}